8-K: Larimar Therapeutics Converts Common to Preferred Stock

Larimar Therapeutics exchanged 2.5 million common shares for 250,000 Series A convertible preferred shares with a key investor, increasing authorized preferred stock to 500,000.

Summary

• Larimar Therapeutics, Inc. entered into an exchange agreement with Blue Owl Healthcare Opportunities IV Public Investments LP on January 21, 2026.
• Blue Owl Healthcare Opportunities IV Public Investments LP exchanged 2,500,000 shares of the Company's common stock for 250,000 shares of Series A Convertible Preferred Stock.
• Each share of Series A Convertible Preferred Stock is convertible into 10 shares of the Company's Common Stock, subject to certain limitations, including a 9.99% beneficial ownership limitation that can be reset by the holder.
• The Series A Convertible Preferred Stock generally does not have voting rights, except as required by law or for specific protective provisions related to its terms.
• In the event of liquidation, dissolution, or winding up, the Series A Convertible Preferred Stock participates pari passu with any distribution of proceeds to holders of Common Stock.
• The Series A Convertible Preferred Stock ranks senior to junior securities, on parity with Common Stock and parity securities, and junior to senior securities in liquidation.
• The Company filed a Certificate of Amendment to the Certificate of Designation on January 21, 2026, to increase the authorized number of shares of Series A Convertible Preferred Stock from 250,000 shares to 500,000 shares.
• The exchange is expected to close on January 23, 2026, and the Series A Convertible Preferred Stock will be issued without registration under Section 3(a)(9) of the Securities Act of 1933.

Sentiment

Score: 6

Explanation: The transaction is a neutral capital structure adjustment. It offers potential positives in managing a large investor's position and providing corporate flexibility, but also introduces potential future dilution from the convertible preferred shares. The 'toothless' nature of the preferred stock mitigates some negative aspects.

Positives

• The Series A Convertible Preferred Stock is described as 'toothless,' meaning it generally does not have superior voting rights (except as required by law or for adverse changes to its terms) or liquidation preferences over common stock, which is favorable for existing common shareholders.
• The exchange allows a significant investor to adjust their equity position without immediately impacting the public float of common stock, potentially reducing immediate selling pressure.

Negatives

• The increase in authorized Series A Convertible Preferred Stock from 250,000 to 500,000 shares creates potential for future dilution if additional preferred shares are issued and subsequently converted into common stock.
• While the immediate common share count held by the specific investor is reduced, the 250,000 Series A Preferred Shares are convertible into 2,500,000 common shares, representing future potential dilution.

Risks

• Future dilution risk from the conversion of the 250,000 Series A Convertible Preferred Stock into 2,500,000 common shares.
• The beneficial ownership limitation (initially 9.99%) can be reset by the holder, potentially allowing for larger conversions in the future.
• The increase in authorized Series A Convertible Preferred Stock to 500,000 shares could facilitate further issuances of this security, leading to additional future dilution.

Future Outlook

The increase in authorized Series A Convertible Preferred Stock suggests potential for future similar transactions or capital raises using this instrument, providing the company with flexibility in its capital structure.

Management Comments

• Carole S. Ben-Maimon, M.D., President and Chief Executive Officer, signed the Exchange Agreement and the Certificate of Amendment on behalf of Larimar Therapeutics, Inc.

Industry Context

This type of capital structure adjustment, involving the exchange of common stock for convertible preferred stock, is a common strategy for companies, particularly in the biotechnology sector, to manage significant investor positions, provide tailored securities, or prepare for future financing rounds. It offers flexibility in managing shareholder base and potential dilution.

Comparison to Industry Standards

• The use of Section 3(a)(9) of the Securities Act for an exchange with an existing security holder is a standard and common exemption for such transactions.
• The structure of the Series A Convertible Preferred Stock, described as 'toothless' with pari passu liquidation rights and limited voting rights (except for protective provisions), is often designed to be less disruptive to common shareholders compared to traditional preferred stock with superior preferences, aligning with practices aimed at minimizing adverse impact on existing equity.

Corporate Governance

Related Party Transactions

• The exchange agreement was entered into with Blue Owl Healthcare Opportunities IV Public Investments LP, a significant institutional investor.

Stakeholder Impact

• Shareholders (Common): Face potential future dilution upon conversion of the Series A Convertible Preferred Stock. The immediate reduction in common shares held by Blue Owl may reduce selling pressure, but the preferred shares represent a future claim on common equity.
• Blue Owl Healthcare Opportunities IV Public Investments LP: Now holds Series A Convertible Preferred Stock, which provides specific conversion rights and protective provisions, potentially offering a different risk/reward profile compared to holding common stock directly.

Next Steps

• The exchange of common stock for Series A Convertible Preferred Stock is expected to close on January 23, 2026.

Key Dates

Keywords

Larimar Therapeutics, LRMR, Convertible Preferred Stock, Equity Exchange, Capital Structure, Blue Owl Healthcare, Unregistered Securities, Corporate Governance, Stock Conversion, Biotechnology